KARL STORZ Flexible Video Neuro-Endoscope
Karl Storz SE & CO. KG · Decision date Oct 14, 2026
What did the FDA decide?
The FDA recorded a substantially equivalent (SESE) decision on 14 October 2026 for K260581, a 510(k) premarket notification submitted by Karl Storz SE & CO. KG of Tuttlingen, Germany. The submission was received on 20 February 2026 and reviewed under product code GWG in the Neurology medical specialty. SESE means the device was cleared as substantially equivalent to a predicate; it is not a premarket approval of the device.
The record identifies the subject as the KARL STORZ Flexible Video Neuro-Endoscope. The available source fields do not describe the specific components, design changes, or predicate device, and no summary statement is present, so the basis for the equivalence determination and any labeled indications remain unknown from this record. The listed page date of 2 November 2026 differs from the 14 October 2026 decision date; the reason is not stated in the source.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Neurology
- Decision date
- Oct 14, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260581
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Karl Storz SE & CO. KG
- Product code
- GWG
- Decision code
- SESE
- Decision date
- Oct 14, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Endoscope, Neurological.
- Applicant
- Karl Storz SE & CO. KG
- Product code
- GWG
- FDA device class
- 2
FDA decision timeline
K260581 received
Application receipt date recorded by FDA.
K260581 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code GWG
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cCeLL - In vivoK260315 | VPIX MEDICAL, INC. | 510(k) clearance | Oct 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Karl Storz SE & CO. KG
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Tuttlingen
Sources and methodology
- Original FDA record: K260581
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records